Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
- Summary
- This is a Phase I, first-in-human, randomized, modified double-blind, active-controlled, dose-escalation study to assess the safety and immunogenicity of up to 3 dose levels of mRNA NA vaccines, administered as a single IM injection in healthy adults aged 18 years and older. Two age groups, 18 to 64 years and ≥65 years, will be included in this study.
- Short title
- Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
- Official title
- Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
- Control arm
- Active comparator
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Completion date
- 2024-01-03
- First posted
- 2022-06-21
- Registry last updated
- 2025-09-15
- Primary completion date
- 2024-01-03
- Start date
- 2022-06-09
- Actual participants
- Participants
- Participant count basis
- Actual
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT05426174
- ClinicalTrials.gov ID
- NCT05426174
- Registry record
- Open registry record
- Allocation
- Randomised
- Model
- Parallel groups
- Purpose
- Prevention
- Masking
- Triple masking
- Masking description
- This study will be blinded to participants, investigators/sub-investigators, outcomes assessors, laboratory personnel, and the sponsor study staff (with the exception noted for study staff involved in the ESDRs). Study staff involved in the ESDRs will be unblinded to group assignment of participants in the sentinel safety cohorts. After the ESDRs are performed for the sentinel safety cohorts, the SMT will continue monitoring the safety aspects of the study as part of blinded periodic safety reviews. Those preparing/administering the study interventions will be unblinded.
- Masked roles
- Participants, Investigators, Outcome assessors
Number of participants with immediate adverse events
Timeframe: Within 30 minutes after vaccination
Immediate adverse events are unsolicited systemic adverse events reported in the 30 minutes after vaccination
Number of participants with solicited injection site or systemic reaction
Timeframe: From Day 1 to Day 8
Number of participants with unsolicited adverse events
Timeframe: From Day 1 to Day 29
Unsolicited (spontaneously reported) adverse events not fulfilling criteria for solicited reactions
Number of participants with serious adverse events
Timeframe: From Day 1 to Day 366
Serious adverse events are collected throughout the study
Number of participants with adverse events of special interest
Timeframe: From Day 1 to Day 366
Adverse events of special interest are collected throughout the study
Number of patients with clinically significant changes in clinical laboratory tests
Timeframe: From Day 1 to Day 8
Laboratory tests include hematology: complete blood count (CBC) with differential, platelet count, coagulation panel (prothrombin time and PTT) and serum chemistry: alanine aminotransferase (ALT), aspartate aminotransferase (AST), total and fractionated bilirubin, C-reactive protein, serum creatinine, and blood urea nitrogen
Neuraminidase inhibition (NAI) Antibodies at Day 1 and 29
Timeframe: Day 1 and 29
Antibody are expressed as GMTs at baseline and post-baseline
Individual Neuraminidase inhibition (NAI) titer
Timeframe: Day 1 and Day 29
Antibody titers are expressed as GMTs at baseline and post-baseline
2-fold and 4-fold rise in NAI antibody titers
Timeframe: From Day 1 to Day 29
Expressed as percentage post-baseline
Percentage of participants with detectable antibody titers greater than or equal to (≥) 10 [1/dil]
Timeframe: Day 1 and Day 29
Expressed as percentage at baseline and post-baseline
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Healthy volunteers
- Yes
-
Aged 18 years or older on the day of inclusion.
-
A female participant is eligible to participate if she is not pregnant or breastfeeding and one of the following conditions applies:
- Is of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile OR
- Is of childbearing potential and agrees to use an effective contraceptive method or abstinence from at least 4 weeks prior to study intervention administration until at least 12 weeks after study intervention administration
-
A female participant of childbearing potential must have a negative highly sensitive pregnancy test (urine or serum as required by local regulation) within 8 hours before administration of study intervention.
-
Informed consent form has been signed and dated.
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- Known systemic hypersensitivity to any of the study intervention components; history of a life-threatening reaction to the study interventions used in the study or to a product containing any of the same substances
- Moderate or severe acute illness/infection (according to investigator judgement) or febrile illness (temperature ≥100.4°F) on the day of study intervention administration.
- Have known or recently active (12 months) neoplastic disease or a history of any hematologic malignancy.
- Have any diagnosis, current or past, of autoimmune disease.
- Body mass index of 40 kg/m2 or higher.
- Receipt of immune globulins, blood, or blood-derived products in the past 3 months.
- Have taken high-dose inhaled corticosteroid (≥500 μg of fluticasone) within 6 months prior to study vaccination.
- Self-reported or documented seropositivity for HIV, hepatitis B virus, or hepatitis C virus.
- AES - DRS - Optimal Research_Site 8400007Huntsville, United States
- Central Phoenix Medical Clinic, LLC_Site: 8400010Phoenix, United States
- Optimal Research San Diego, LLC_Site: 8400009San Diego, United States
- AES - DRS - Optimal Research_Site 8400002Melbourne, United States
- AES - DRS - Optimal Research_Site 8400001Peoria, United States
- Synexus Clinical Research_Site 8400003Cincinnati, United States
Other registry identifiers
- U1111-1266-5326